Supplementary Tables from Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Supplementary Table S1. The pathway classification of metabolites used for the MSEA Supplementary Table S2. Genetic profiles in 42 SCLC cell lines Supplementary Table S3. Quantitative phospho-peptide analysis in H1048 cells with or without Gedatolisib treatment Supplementary Table S4. Quantitative phosphatidyl lipids analysis in SCLC cell Supplementary Table S5. Quantitative phosphatidyl lipids analysis in H1048 cells Supplementary Table S6. 116 metabolites in SCLC cells with or without Gedatolisib treatment Supplementary Table S7. 116 metabolites in H1048 and SBC5 with or without Gedatolisib treatment Supplementary Table S8. Metabolite set enrichment analysis (MSEA) to identify significantly enriched metabolic pathways related to gedatolisib Supplementary Table S9. Amount of 116 metabolites in SCLC tissues